CTLA4 and Miyoshi myopathy: A large analysis exploring the efficacy of ICIs in MM compared to cutaneous melanoma showed that nivolumab (anti-PD-1) combined with ipilimumab (anti-CTLA-4) had a greater efficacy than either agent alone for both diseases [26].